Compare Teucrium Corn Fund (CORN) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teucrium Corn Fund vs Citius Pharmaceuticals Inc — how do they compare? Teucrium Corn Fund trades at $17.69, while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: Teucrium Corn Fund is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CORN | CTXR | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $19.12 | $1.82 |
52-Week Low | $16.46 | $0.48 |
Market Cap | — | $18.73M |
Enterprise Value | — | $14.95M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CORN trades at $17.64, up 0.17% for the day, with technical indicators showing a bearish bias from moving averages despite a neutral oscillator stance and oversold short-term RSI. Recent news highlights strong performance in agricultural ETFs, with CORN returning 9.7% over the past month, driven by inflation trends and geopolitical tensions affecting commodity markets.
The outlook is mixed; positive momentum from commodity strength offers upside, but bearish technicals and reliance on volatile agricultural markets pose risks. Investors should weigh near-term commodity tailwinds against the absence of fundamental financial data and broader market sentiment shifts.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Teucrium Corn Fund
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
